美单日新增逾7.1万宗新冠确诊 辉瑞及Moderna将加倍生产疫苗
美国新冠疫情回落。据美国约翰霍普金斯大学统计,美国截至西岸时间午夜(本港时间下午4时),累计新冠确诊28,261,585宗,单日新增71,182宗。累计死亡个案502,660宗,单日新增2,350宗。各州疫情方面,加州累计确诊354.33万宗,德克萨斯州累计确诊261.71万宗,佛罗里达、纽约及伊利诺伊州各累计确诊187.85万、160.49万及117.72万宗,乔治亚州为99.08万宗。
《CNBC》报道,美国新冠疫苗供应将在下月显着增加,其中辉瑞将在3月中把产量增至每周1,300万剂,为本月初的两倍。Moderna希望在4月达致每月供应4,000万剂疫苗,较目前增加约1倍。美国联邦食品及药物管理局将於明日(25日)检视只须注射一次的强生新冠疫苗,强生预计3月底能够供应逾2,000万剂疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.